Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Transcept receives FDA approval for Intermezzo to treat insomnia

The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.

23 Nov 2011

Dendritic cells play a novel protective role in pancreas

NYU Langone Medical Center researchers have discovered the novel protective role dendritic cells play in the pancreas. The new study, published in the November issue of journal Gastroenterology, shows dendritic cells can safeguard the pancreas against acute pancreatitis, a sudden dangerous swelling and inflammation of the pancreas gland.

23 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

Consistent data from three studies support plans for rindopepimut with ACT IV Phase 3 study

Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).

21 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

FDA approves EUSA's orphan drug ERWINAZE for acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that the US Food and Drug Administration (FDA) has approved its orphan drug ERWINAZE (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to E. coli-derived asparaginase.

19 Nov 2011

New, incision-free surgery to manage chronic acid reflux

Adam Vasser would wake up at night choking on partially digested food and liquid. Stomach acid burned the delicate tissue of his throat. "I'd sleep really badly," he said. During the day, he sometimes suffered from heartburn.

19 Nov 2011

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

18 Nov 2011

EUSA Pharma receives FDA approval for Erwinaze to treat ALL

The U.S. Food and Drug Administration today approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegaspargase chemotherapy drugs used to treat ALL.

18 Nov 2011

New possibilities for relief from digestive diseases

As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.

17 Nov 2011

Potential breakthrough in treating late-stage ovarian cancer

A potential breakthrough in treating late-stage ovarian cancer has come from University of Guelph researchers who have discovered a peptide that shrinks advanced tumours and improves survival rates for this deadly but often undetected disease.

17 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer.

16 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

AMAG Pharmaceuticals, Inc. today announced positive new data from the FIRST head-to-head trial comparing Feraheme (ferumoxytol) Injection for intravenous (IV) use to iron sucrose in patients with iron deficiency anemia and chronic kidney disease.

14 Nov 2011

Conference highlights advances in evidence-based integrative therapies for cancer

Today the Society for Integrative Oncology highlighted top research findings presented at the Eighth International Conference this week in Cleveland, Ohio. More than 80 abstracts will be presented at the annual meeting, which will be keynoted by National Institutes of Health Director, Francis Collins, MD, PhD.

11 Nov 2011

High-powered magnets continue to be a safety risk to children

An increasing number of incident reports to the U.S. Consumer Product Safety Commission (CPSC) indicate that high-powered magnets continue to be a safety risk to children. From toddlers to teens, children are swallowing these magnets and the consequences are severe.

10 Nov 2011

Experimental drug selectively destroys blood supply of fat tissue and decreases body fat

Obese rhesus monkeys lost on average 11 percent of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in Science Translational Medicine.

10 Nov 2011

Positive results from Alkermes VIVITROL addiction study

Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV.

10 Nov 2011

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR or Stalevo, in patients with advanced Parkinson's disease.

9 Nov 2011